Loading...

Aptevo Therapeutics

DB:AP8
Snowflake Description

Imperfect balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AP8
DB
$35M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
  • Aptevo Therapeutics has significant price volatility in the past 3 months.
AP8 Share Price and Events
7 Day Returns
-7.8%
DB:AP8
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-79.9%
DB:AP8
-10.6%
DE Biotechs
-6.2%
DE Market
AP8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aptevo Therapeutics (AP8) -7.8% -5.6% -49.3% -79.9% - -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • AP8 underperformed the Biotechs industry which returned -10.6% over the past year.
  • AP8 underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
AP8
Industry
5yr Volatility vs Market
Related Companies

AP8 Value

 Is Aptevo Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Aptevo Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.69.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aptevo Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aptevo Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AP8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.39
NasdaqGS:APVO Share Price ** NasdaqGS (2019-04-18) in USD $0.81
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aptevo Therapeutics.

DB:AP8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:APVO Share Price ÷ EPS (both in USD)

= 0.81 ÷ -2.39

-0.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aptevo Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Aptevo Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Aptevo Therapeutics's expected growth come at a high price?
Raw Data
DB:AP8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
8.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aptevo Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aptevo Therapeutics's assets?
Raw Data
DB:AP8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.33
NasdaqGS:APVO Share Price * NasdaqGS (2019-04-18) in USD $0.81
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:AP8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:APVO Share Price ÷ Book Value per Share (both in USD)

= 0.81 ÷ 1.33

0.61x

* Primary Listing of Aptevo Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aptevo Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Aptevo Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Aptevo Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AP8 Future Performance

 How is Aptevo Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
8.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aptevo Therapeutics expected to grow at an attractive rate?
  • Unable to compare Aptevo Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Aptevo Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Aptevo Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:AP8 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AP8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 8.3%
DB:AP8 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 20.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AP8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AP8 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 35 -49 1
2019-12-31 29 -43 2
DB:AP8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 23 -51 -54
2018-09-30 20 -60 -49
2018-06-30 20 -50 -34
2018-03-31 17 -47 -35
2017-12-31 15 -42 -33
2017-09-30 15 -33 -39
2017-06-30 11 -31 -115
2017-03-31 4 -35 -119
2016-12-31 10 -37 -120
2016-09-30 15 -38 -122
2016-06-30 19 -47 -61
2016-03-31 30 -47 -61

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aptevo Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Aptevo Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AP8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Aptevo Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AP8 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -1.11 -1.11 -1.11 1.00
2019-12-31 -1.13 -1.04 -1.22 2.00
DB:AP8 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.39
2018-09-30 -2.21
2018-06-30 -1.54
2018-03-31 -1.61
2017-12-31 -1.53
2017-09-30 -1.87
2017-06-30 -5.60
2017-03-31 -5.83
2016-12-31 -5.92
2016-09-30 -6.01
2016-06-30 -3.01
2016-03-31 -3.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aptevo Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Aptevo Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aptevo Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AP8 Past Performance

  How has Aptevo Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aptevo Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aptevo Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Aptevo Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aptevo Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Aptevo Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aptevo Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AP8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 23.07 -53.69 28.13
2018-09-30 19.54 -49.36 30.11
2018-06-30 19.89 -33.78 30.65
2018-03-31 16.59 -34.79 32.04
2017-12-31 14.66 -32.59 34.58
2017-09-30 14.62 -39.06 34.23
2017-06-30 11.27 -115.45 37.90
2017-03-31 4.06 -118.72 36.87
2016-12-31 9.99 -119.89 36.16
2016-09-30 15.49 -121.63 42.09
2016-06-30 19.24 -60.90 39.46
2016-03-31 30.01 -61.18 42.53
2015-12-31 33.60 -59.32 43.04
2014-12-31 45.63 -51.12 34.28
2013-12-31 0.17 -53.34 15.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aptevo Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aptevo Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aptevo Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aptevo Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aptevo Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AP8 Health

 How is Aptevo Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aptevo Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aptevo Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aptevo Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aptevo Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aptevo Therapeutics Company Filings, last reported 3 months ago.

DB:AP8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 30.41 19.28 30.64
2018-09-30 44.00 19.14 37.64
2018-06-30 56.03 19.57 44.73
2018-03-31 68.36 19.31 61.65
2017-12-31 82.04 19.06 80.78
2017-09-30 90.31 17.48 96.78
2017-06-30 51.42 18.75 48.23
2017-03-31 61.49 18.44 60.89
2016-12-31 50.57 18.38 54.53
2016-09-30 63.75 18.11 60.68
2016-06-30 97.20 0.00 5.50
2016-03-31 89.86 0.00 3.07
2015-12-31 88.62 0.00 4.64
2014-12-31 94.61 0.00 3.59
2013-12-31
  • Aptevo Therapeutics's level of debt (63.4%) compared to net worth is high (greater than 40%).
  • Unable to establish if Aptevo Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aptevo Therapeutics has less than a year of cash runway based on current free cash flow.
  • Aptevo Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.9% each year.
X
Financial health checks
We assess Aptevo Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aptevo Therapeutics has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AP8 Dividends

 What is Aptevo Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aptevo Therapeutics dividends.
If you bought €2,000 of Aptevo Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aptevo Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aptevo Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AP8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AP8 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aptevo Therapeutics has not reported any payouts.
  • Unable to verify if Aptevo Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aptevo Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aptevo Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aptevo Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aptevo Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aptevo Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AP8 Management

 What is the CEO of Aptevo Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marvin White
COMPENSATION $1,048,403
AGE 56
TENURE AS CEO 2.7 years
CEO Bio

Mr. Marvin L. White has been the Chief Executive Officer and President at Aptevo Therapeutics Inc. since August 1, 2016. Mr. White has been the President and Chief Executive Officer at The MLW Advisory Group, LLC since April 2014. Mr. White served as Chief Financial Officer and System Vice President at St. Vincent Hospital and Health Care Center, Inc from 2008 to March 2014. He served as Chief Financial Officer at Eli Lilly & Company's Lilly USA, LLC. He served leadership positions at Lilly in Corporate Finance and Investment Banking in the Corporate Strategy Group. He served as the Pharmaceutical Company's Assistant Treasurer. He served as an Executive Director of Eli Lilly & Company's LillyUSA and Lilly pharmaceutical company. Prior to his career in health care, He served with General Motors in Illinois and Hewlett Packard in Atlanta, where he served various supervisory and financial assignments. In 1993, he joined Motorola's Cordless Operation as an Operations Controller and Senior Operations Controller for the Japan Cellular Division since 1995. He moved to Singapore in 1997 as the South Asia Divisional Controller for Motorola's Cellular Sector and served as its Latin America Divisional Controller for the Cellular sector. He served as Chairman of St. Vincent Indianapolis Hospital Board of Directors. He has been a Trustee at HealthLease Properties Real Estate Investment Trust since December 4, 2013. He has been a Director of OneAmerica Financial Insurance Partners, Inc. since September 2014. He serves as a Director of Ryla, Inc. He serves on the Boards of Marian University, Advantage Health Solutions, Inc. Mr. White served as an Independent Director of CoLucid Pharmaceuticals, Inc. since July 13, 2015 until March 1, 2017. He serves as an Independent Director of WP GLIMCHER Inc. from May 7, 2014. He served as a Director of Emergent BioSolutions, Inc. since June 2010 until May 26, 2016. He served as a Director of Lilly USA, LLC. He is active with the Center for Leadership Development, Saving Orphans through Healthcare and Outreach (SOHO) and with the United Way. He has been a Director at Aptevo Therapeutics Inc. since August 1, 2016. He served as a Member of the Arts Council of Indianapolis and the Lynxx Capital Corporation Investment Committee. Mr. White received Master's degree in Business Administration in Finance from Indiana University in 1989 and a Bachelor's degree in Accounting from Wilberforce University in 1984.

CEO Compensation
  • Marvin's compensation has increased whilst company is loss making.
  • Marvin's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Aptevo Therapeutics management team in years:

2.8
Average Tenure
56.5
Average Age
  • The tenure for the Aptevo Therapeutics management team is about average.
Management Team

Marvin White

TITLE
President
COMPENSATION
$1M
AGE
56
TENURE
2.7 yrs

Jeff Lamothe

TITLE
Senior VP
COMPENSATION
$671K
AGE
52
TENURE
2.8 yrs

Scott Stromatt

TITLE
Senior VP of Clinical Development & Medical Affairs and Chief Medical Officer
COMPENSATION
$683K
AGE
60
TENURE
2.8 yrs

Randy Maddux

TITLE
Senior VP of Operations & Chief Manufacturing Officer
AGE
57
TENURE
2.8 yrs

Jane Gross

TITLE
Senior VP & Chief Scientific Officer
AGE
61
TENURE
2.6 yrs

Stacey Jurchison

TITLE
Senior Director of Investor Relations & Corporate Communications

Shawnte Mitchell

TITLE
Senior VP of Corporate Affairs & General Counsel
TENURE
2.8 yrs

Mike Adelman

TITLE
Senior VP of Commercial Operations
AGE
47
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Aptevo Therapeutics board of directors in years:

2.7
Average Tenure
62
Average Age
  • The average tenure for the Aptevo Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Fuad El-Hibri

TITLE
Chairman
COMPENSATION
$72K
AGE
60
TENURE
2.7 yrs

Marvin White

TITLE
President
COMPENSATION
$1M
AGE
56
TENURE
2.7 yrs

Zsolt Harsanyi

TITLE
Independent Director
COMPENSATION
$96K
AGE
74
TENURE
2.7 yrs

Barbara Kunz

TITLE
Independent Director
COMPENSATION
$97K
AGE
60
TENURE
2.7 yrs

John Niederhuber

TITLE
Lead Independent Director
COMPENSATION
$100K
AGE
79
TENURE
2.7 yrs

Dan Abdun-Nabi

TITLE
Director
COMPENSATION
$69K
AGE
63
TENURE
2.7 yrs

Grady Grant

TITLE
Independent Director
COMPENSATION
$92K
AGE
62
TENURE
2.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Dec 18 Buy Randy Maddux Individual 06. Dec 18 06. Dec 18 5,000 €2.08 €10,421
06. Dec 18 Buy Marvin White Individual 04. Dec 18 04. Dec 18 10,000 €2.10 €20,961
X
Management checks
We assess Aptevo Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aptevo Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AP8 News

Simply Wall St News

AP8 Company Info

Description

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The company’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.

Details
Name: Aptevo Therapeutics Inc.
AP8
Exchange: DB
Founded: 2016
$30,927,778
42,940,219
Website: http://www.aptevotherapeutics.com
Address: Aptevo Therapeutics Inc.
2401 4th Avenue,
Suite 1050,
Seattle,
Washington, 98121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS APVO Common Shares Nasdaq Global Select US USD 01. Aug 2016
DB AP8 Common Shares Deutsche Boerse AG DE EUR 01. Aug 2016
LSE 0HH3 Common Shares London Stock Exchange GB USD 01. Aug 2016
Number of employees
Current staff
Staff numbers
118
Aptevo Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 22:07
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.